Actively Recruiting
Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
Led by Brigham and Women's Hospital · Updated on 2025-10-14
6
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine the safety of moderately hypofractionated radiation in the treatment of primary and locally recurrent RPS, based on the evaluation of acute radiation-related toxicity profile of each participant (30-day radiation toxicity)
CONDITIONS
Official Title
Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed soft tissue sarcoma of the retroperitoneal or infra-peritoneal pelvic space
- Radiologically measurable disease by abdomino-pelvic CT or MRI
- Primary, locally recurrent, or metastatic disease requiring treatment of the retroperitoneal mass
- Tumor suitable for radiotherapy and surgery with expected complete or near-complete resection
- Age 18 years or older
- ECOG performance status of 0, 1, or 2
- No history of bowel obstruction, mesenteric ischemia, or severe chronic inflammatory bowel disease
- Normal kidney function with creatinine clearance of 50 mL/min or higher
- Normal bone marrow and liver function (adequate blood counts and bilirubin below twice the upper limit)
- Negative pregnancy test within 3 weeks before starting treatment for women of childbearing potential
- Use of adequate contraception if capable of childbearing
- Ability to understand and willing to sign informed consent
You will not qualify if you...
- Sarcoma originating from bone, abdominal, or gynecological organs
- Histological subtypes including gastrointestinal stromal tumor, rhabdomyosarcoma, primitive neuroectodermal tumor, small round blue cell sarcoma, osteosarcoma, chondrosarcoma, aggressive fibromatosis, sarcomatoid or metastatic carcinoma
- Prior radiation therapy to the retroperitoneal sarcoma area
- Previous abdominal or pelvic radiation for other diseases
- Chemotherapy or immunotherapy within 6 weeks before starting radiation
- Pregnant women
- HIV-positive individuals on combination antiretroviral therapy
- Prior different invasive malignancy unless approved by the investigator and principal investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Brigham and Women's Hospital / Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02446
Actively Recruiting
Research Team
M
Miranda Lam
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here